Evidence map›Paper›PMID 28373061›Full record

ArticleVirus research2017

Sequence analysis and functional characterization of full-length hepatitis B virus genomes from Korean cirrhotic patients with or without liver cancer.

Huailiang Zhou, Dina Gewaily, Sang Hoon Ahn, Carina Preskill, Yongxiang Wang, Li Zong, Jing Zhang, Kwang-Hyub Han, Jack Wands, Jisu Li and 1 more

Open access · greenAbstract read
In one paragraph

Article in Virus research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Huailiang ZhouKey Lab of Medical Molecular Virology School of Basic Medical Sciences Fudan University Shanghai, China. Electronic address: 1661753336@qq.com.
Dina GewailyLiver Research Center, Rhode Island Hospital, Warren Alpert School of Medicine, Brown University, Providence, RI, USA 1661753336@qq.com. Electronic address: dina.gewaily@gmail.com.
Sang Hoon AhnDepartment of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: ahnsh@yuhs.ac.
Carina PreskillLiver Research Center, Rhode Island Hospital, Warren Alpert School of Medicine, Brown University, Providence, RI, USA 1661753336@qq.com. Electronic address: cpreskil@brown.edu.
Yongxiang WangKey Lab of Medical Molecular Virology School of Basic Medical Sciences Fudan University Shanghai, China. Electronic address: yxwang712@yahoo.com.
Li ZongKey Lab of Medical Molecular Virology School of Basic Medical Sciences Fudan University Shanghai, China. Electronic address: zongli1226@163.com.
Jing ZhangKey Lab of Medical Molecular Virology School of Basic Medical Sciences Fudan University Shanghai, China. Electronic address: 2471633990@qq.com.
Kwang-Hyub HanDepartment of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: gihankhys@yuhs.ac.
Jack WandsLiver Research Center, Rhode Island Hospital, Warren Alpert School of Medicine, Brown University, Providence, RI, USA 1661753336@qq.com. Electronic address: jack_wands_md@brown.edu.
Jisu LiLiver Research Center, Rhode Island Hospital, Warren Alpert School of Medicine, Brown University, Providence, RI, USA 1661753336@qq.com. Electronic address: ji_su_li_md@brown.edu.
Shuping TongKey Lab of Medical Molecular Virology School of Basic Medical Sciences Fudan University Shanghai, China; Liver Research Center, Rhode Island Hospital, Warren Alpert School of Medicine, Brown University, Providence, RI, USA 1661753336@qq.com. Electronic address: shuping_tong_md@brown.edu.
Fudan University · CNJohn Brown University · USYonsei University · KR

Funding

Hepatitis B virus vaccine escape mutantsR01AI116639 · NIAID · RHODE ISLAND HOSPITAL · PI TONG, SHUPING · 2015 to 2019
$1.8M
Hepatitis B virus transcriptional interference and liver cancer-related mutationsR21AI113394 · NIAID · RHODE ISLAND HOSPITAL · PI TONG, SHUPING · 2015 to 2016
$443k
Hepatitis B virus genotypes B and CR21AI103648 · NIAID · RHODE ISLAND HOSPITAL · PI TONG, SHUPING · 2013 to 2014
$437k
Control of HBV replication at the step of core and P protein translationR21AI107618 · NIAID · RHODE ISLAND HOSPITAL · PI LI, JISU · 2013 to 2014
$423k
NIAID NIH HHS R01 AI116639NIAID NIH HHS R21 AI103648NIAID NIH HHS R21 AI107618NIAID NIH HHS R21 AI113394
6 · The paper itself

Abstract

This study aimed to identify and characterize mutations in the hepatitis B virus (HBV) genome associated with advanced liver diseases. The 3.2-kb HBV genome of the C2 subgenotype was amplified from sera of 18 cirrhotic Korean patients with (10) or without (8) hepatocellular carcinoma (HCC), and two clones per patient were characterized by transient transfection experiments in human hepatoma cells. While A1762T/G1764A core promoter mutations were highly prevalent in both groups, the G1896A precore mutation to abolish hepatitis B e antigen (HBeAg) expression was more common in HCC clones (55% vs. 20%). High replication capacity was mostly found in HCC clones and associated with core promoter mutations, whereas more non-HCC clones harbored a nonfunctional core gene (34% vs. 8%). Large in-frame deletions in the preS region were found in 60% of HCC clones and 38% of non-HCC clones. They removed the first 11 residues of large envelope protein or impaired small envelope protein expression, or deleted a neutralizing epitope in the preS2 domain. Additional point mutations prevented middle envelope protein expression, or caused nonsense mutations in the preS or S region to truncate large and/or small envelope protein. Consequently, many clones were unable to express or secrete hepatitis B surface antigen (HBsAg). In conclusion, mutations associated with the advanced stage of chronic HBV infection are complex and diverse. Host immune pressure most likely selected for mutations in the HBV genome to abolish or reduce HBeAg or HBsAg production, to enhance genome replication, or to escape neutralizing antibodies. Some of these mutations may contribute to liver cirrhosis or HCC development.

Indexed as

Genetic VariationMutationAsian PeopleCell Line, TumorGenome, ViralGenotypeHepatitis B, ChronicHepatitis B virusHumansLiver CirrhosisLiver NeoplasmsSequence AnalysisVirus ReplicationCore promoter mutationsGenome replicationHepatitis B surface antigenHepatitis B virusLiver cancerPreS deletions

Identifiers

PMID28373061
PMCPMC6372094
OpenAlexW2599921335

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.